Skip to Content

Fasenra Approval History

  • FDA approved: Yes (First approved November 14th, 2017)
  • Brand name: Fasenra
  • Generic name: benralizumab
  • Dosage form: Injection
  • Company: AstraZeneca
  • Treatment for: Asthma

Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.

Development History and FDA Approval Process for Fasenra

DateArticle
Nov 14, 2017Approval FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma
May 22, 2017Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients
Sep  5, 2016Benralizumab Phase III Trials Show Positive Results in Severe Asthma
May 17, 2016AstraZeneca Announces Positive Results from Benralizumab Phase III Programme in Severe Asthma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide